Menu

Pfizer Inc. PFE

Full chart Compare
Set alert

Price alert · PFE

All alert types
29.39 USD -0.06 (-0.20%)

At closeNov 6, 2026, 7:58 PM EST

29.35 -0.04 -0.14%

After hours · Nov 6, 7:58 PM ET

28.54 Day range 29.43
23.67 52-week range 30.79
YTD
+18.03%
1 year
+18.27%
Market cap
167.52B
Revenue (ttm)
63.62B
Profit margin
6.34%
EPS (ttm)
0.70
Shares out
5.70B
P/E ratio
41.99
Forward P/E
10.04
Dividend
1.72 (5.76%)
Ex-dividend date
Nov 5, 2026
YTD return
+18.03%
1-year return
+18.27%
Volume
48.32M
Avg volume
34.07M
Open
29.07
Previous close
29.45
Day's range
28.54 – 29.43
52-week range
23.67 – 30.79
Beta
0.30
Analysts
Buy
Price target
29.72 (+1.1%)
Earnings date
Feb 2, 2027

5D -1.09 (-3.58%)

293031MonTueWedThuFri29.39

Key statistics

Enterprise value
219.74B
PEG ratio
13.69
Price / sales
2.63
Price / book
1.88
Dividend yield
5.76%
Payout ratio
245.71%
Revenue growth
-0.40%
Free cash flow
13.01B
Total cash
14.28B
Total debt
63.41B
Return on equity
4.47%
Short % of float
2.42%
50-day average
28.72
200-day average
26.89

Financials — quick view

All financials
PFE Revenue — quarterly 16.58B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PFE Net income — quarterly 3.24B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PFE EPS — quarterly 0.57
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

PFE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 2, 2027Dec 27, 20260.72———
Nov 3, 2026Sep 27, 20260.7350.87+0.14+18.37%
Aug 4, 2026Jun 28, 20260.6820.77+0.09+12.90%
May 5, 2026Mar 29, 20260.7220.75+0.03+3.88%
Feb 3, 2026Dec 31, 20250.5670.66+0.09+16.40%
Nov 4, 2025Sep 28, 20250.6330.87+0.24+37.44%

Upgrades / downgrades

PFE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026GuggenheimmainBuyBuy
Nov 4, 2026UBSmainNeutralNeutral
Nov 4, 2026ScotiabankmainSector OutperformSector Outperform
Nov 4, 2026CitigroupmainNeutralNeutral
Nov 4, 2026RBC CapitalmainSector PerformSector Perform
Oct 9, 2026JP MorganmainNeutralNeutral

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
pfizer.com

News

Your note

Sign in to keep a note on PFE — it syncs with the Stock Master app.

Insider holders

PFE insider holders
InsiderRelationLatest transactionDateShares held
BLAYLOCK RONALD EDirectorPurchaseAug 4, 202671,688
BOSHOFF CHRISTOFFELOfficerStock Award(Grant)Feb 24, 2026162,088
BOURLA ALBERTChief Executive OfficerPurchaseAug 11, 2026435,555
BUCKLEY MORTIMER J.DirectorPurchaseAug 4, 202637,632
DAMICO JENNIFER B.OfficerSaleAug 4, 202628,611
FONSECA LIDIA PH.D.OfficerConversion of Exercise of derivative securityFeb 24, 202646,455

Institution ownership

PFE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.29%529,670,43315.57BJun 29, 2026
Vanguard Capital Management LLC6.53%372,149,85210.94BJun 29, 2026
State Street Corporation5.39%307,090,8979.03BJun 29, 2026
Geode Capital Management, LLC2.37%135,275,7823.98BJun 29, 2026
Vanguard Portfolio Management LLC2.09%119,235,0303.50BJun 29, 2026
Fisher Asset Management, LLC1.91%109,067,2913.21BJun 29, 2026

Fund ownership

PFE fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%180,944,8985.32BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%147,700,0664.34BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%75,946,8892.23BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%74,072,7172.18BSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%70,581,6112.07BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Value Index Fund0.95%54,248,0961.59BJun 29, 2026